Perspectives and controversies regarding the use of natural products for the treatment of lung cancer
Open Access
- 2 March 2021
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 10 (7) , 2396-2422
Abstract
Lung cancer is the leading cause of cancer‐related mortality both in men and women and accounts for 18.4% of all cancer‐related deaths. Although advanced therapy methods have been developed, the prognosis of lung cancer patients remains extremely poor. Over the past few decades, clinicians and researchers have found that chemical compounds extracted from natural products may be useful for treating lung cancer. Drug formulations derived from natural compounds, such as paclitaxel, doxorubicin, and camptothecin, have been successfully used as chemotherapeutics for lung cancer. In recent years, hundreds of new natural compounds that can be used to treat lung cancer have been found through basic and sub‐clinical research. However, there has not been a corresponding increase in the number of drugs that have been used in a clinical setting. The probable reasons may include low solubility, limited absorption, unfavorable metabolism, and severe side effects. In this review, we present a summary of the natural compounds that have been proven to be effective for the treatment of lung cancer, as well as an understanding of the mechanisms underlying their pharmacological effects. We have also highlighted current controversies and have attempted to provide solutions for the clinical translation of these compounds.Keywords
This publication has 264 references indexed in Scilit:
- Therapeutic potential of snake venom in cancer therapy: current perspectivesAsian Pacific Journal of Tropical Biomedicine, 2013
- Active Component of Danshen (Salvia miltiorrhizaBunge), Tanshinone I, Attenuates Lung Tumorigenesis via Inhibitions of VEGF, Cyclin A, and Cyclin B ExpressionsEvidence-Based Complementary and Alternative Medicine, 2013
- A Phase II Study of Halichondrin B Analog Eribulin Mesylate (E7389) in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with a Taxane: A California Cancer Consortium TrialJournal of Thoracic Oncology, 2012
- Gambogic acid enhances proteasome inhibitor-induced anticancer activityCancer Letters, 2011
- Silibinin Prevents Lung Tumorigenesis in Wild-Type but not in iNOS−/− Mice: Potential of Real-Time Micro-CT in Lung Cancer Chemoprevention StudiesClinical Cancer Research, 2011
- Enhanced inhibition of lung adenocarcinoma by combinatorial treatment with indole-3-carbinol and silibinin in A/J miceCarcinogenesis, 2011
- Silibinin inhibits human nonsmall cell lung cancer cell growth through cell‐cycle arrest by modulating expression and function of key cell‐cycle regulatorsMolecular Carcinogenesis, 2009
- Growth Inhibition and Regression of Lung Tumors by Silibinin: Modulation of Angiogenesis by Macrophage-Associated Cytokines and Nuclear Factor-κB and Signal Transducers and Activators of Transcription 3Cancer Prevention Research, 2009
- Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cellsMolecular Cancer Therapeutics, 2008
- p53 cooperates berberine‐induced growth inhibition and apoptosis of non‐small cell human lung cancer cells in vitro and tumor xenograft growth in vivoMolecular Carcinogenesis, 2008